Cardiovascular Calcification: Unraveling the Mechanisms, Clinical Impact and Therapeutic Challenges
H.P Riswati *
Brawijaya University, Medical Faculty, Malang, East Java, Indonesia.
M.S Rohman
Department of Cardiology, Brawijaya University, Medical Faculty, Malang, East Java, Indonesia.
C.T Tjahjono
Department of Cardiology, Brawijaya University, Medical Faculty, Malang, East Java, Indonesia.
*Author to whom correspondence should be addressed.
Abstract
Cardiovascular calcification is a pathological process characterized by the deposition of calcium phosphate within vascular structures and cardiac valves. Long considered a passive byproduct of aging and degenerative disease, Cardiovascular calcification is now understood to be an actively regulated biological phenomenon driven by cellular differentiation, inflammatory pathways, oxidative stress, and disordered mineral metabolism. Its presence is strongly associated with increased cardiovascular morbidity and mortality, including coronary artery disease, heart failure due to valvular stenosis, and complications of chronic kidney disease. At the cellular level, cardiovascular calcification arises from the transdifferentiation of vascular smooth muscle cells (VSMCs) and valve interstitial cells (VICs) into osteoblast-like cells. This phenotypic shift is orchestrated by key transcription factors such as Runx2, Msx2, and osterix, which induce the expression of bone matrix proteins and enzymes that facilitate calcification. Simultaneously, an imbalance between pro-calcific mediators and anti-calcific inhibitors further accelerates mineral deposition. Inflammation and oxidative stress amplify these effects, while cell death and extracellular matrix remodeling provide the structural basis for calcium accumulation.
Several systemic conditions increase susceptibility to cardiovascular calcification, including advanced age, diabetes, hypertension, chronic kidney disease, and autoimmune disorders. Genetic syndromes such as generalized arterial calcification of infancy (GACI) and pseudoxanthoma elasticum (PXE) highlight the importance of disrupted mineral metabolism and extracellular inhibitors in pathogenesis. Clinically, imaging modalities such as computed tomography (CT) and biomarkers like microRNAs and extracellular vesicles are gaining traction for diagnosis and monitoring. Despite its clinical relevance, effective therapies targeting cardiovascular calcification remain lacking. This review underscores the necessity for early detection strategies, biomarker-guided interventions, and tailored treatments that account for the calcification's type, location, and underlying pathophysiology. Continued research is crucial to improvement is better outcomes in patients affected by this complex and multifaceted disease.
Keywords: Cardiovascular calcification, Vascular Smooth Muscle Cells (VSMCs), cardiac valves, oxidative stress